Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 13/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.41 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.41 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27915724 | 0.89 | AAK1 (0.46) | AAK1HDAC1CYP17A1KCNQ4KCNQ5 | |
| SCHEMBL28046953 | 0.84 | KCNQ4 (0.45) | AAK1HDAC1CYP17A1KCNQ4KCNQ5 | |
| SCHEMBL30002232 | 0.84 | KCNQ4 (0.45) | AAK1HDAC1CYP17A1KCNQ4KCNQ5 | |
| SCHEMBL1726357 | 0.82 | LMNA (0.51) | AAK1CYP17A1KCNQ4KCNQ5 | |
| SCHEMBL3407965 | 0.82 | HPGD (0.49) | AAK1HDAC1HDAC2HDAC3 | |
| SCHEMBL29741562 | 0.82 | HPGD (0.49) | AAK1HDAC1HDAC2HDAC3 | |
| SCHEMBL2227781 | 0.82 | AAK1 (0.48) | AAK1HDAC1HDAC2HDAC3NR1H2 | |
| SCHEMBL25934416 | 0.82 | HDAC1 (0.46) | AAK1HDAC1HDAC2HDAC3KCNQ4 | |
| SCHEMBL29468015 | 0.82 | CYP17A1 (0.49) | AAK1CYP17A1KCNQ4KCNQ5 | |
| SCHEMBL12209772 | 0.82 | KCNQ4 (0.42) | AAK1HDAC1CYP17A1KCNQ4KCNQ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105307657-A | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RES INC | 2016-02-03 | — | — | CN | disclosed |
| CN-105188371-A | Erk inhibitors and uses thereof | CELGENE AVILOMICS RES INC | 2015-12-23 | — | — | CN | disclosed |
| US-20010049374-A1 | Urokinase inhibitors | STEELE ANDREW W (US) | 2001-12-06 | — | — | US | disclosed |
| US-6284796-B1 | NAPHTHAMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-09-04 | — | — | US | disclosed |
| US-6258822-B1 | ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-07-10 | — | — | US | disclosed |
| EP-1000018-A2 | UROKINASE INHIBITORS | Abbott Laboratories (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999005096-A2 | UROKINASE INHIBITORS | ABBOTT LABORATORIES (US) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | SERPINE1, PLAU, SERPINB1 | AAK1 771/4885HDAC1 1182/4885CYP17A1 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.